Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Tesla Semi Rollout Begins at Nevada Factory 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
3 clinical-grade skincare creams you really shouldn’t buy online 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Add as a preferred source on Google
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
